{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Table 9.1', 'Restricted Medications and Therapies', 'Medication/Therapy', 'Restricted Dose or Time Period', 'Orbital irradiation for TED', 'Any history or planned procedure during entire study', 'duration (Screening through Week 72 of Follow-Up Period).', 'Eye surgery for TED', 'Any history or planned procedure during entire study', 'duration (Screening through Week 72 of Follow-Up Period).', 'Steroids for treatment of TED', 'Any history of steroid use (IV or oral) with a cumulative', 'dose equivalent to > 1 g of methylprednisolone for the', 'treatment of TED is excluded.', 'Previous steroid use (IV or oral) with a cumulative dose <1 g', 'methylprednisolone or equivalent for the treatment of TED is', 'allowed if the corticosteroid was discontinued at least', '4 weeks prior to Screening.', 'Steroid eye drops must be discontinued at least 4 weeks prior', 'to screening.', 'Steroids (IV or oral) for treatment of TED and steroid eye', 'drops are not allowed during the entire study duration.', 'Steroids for conditions other than TED', 'Previous steroid use for conditions other than TED is', 'allowed but must be discontinued at least 4 weeks prior to', 'Screening.', 'Topical steroids for dermatological conditions and inhaled', 'steroids are allowed during the study.', 'IV dexamethasone for infusion-associated AEs is allowed', '(see Section 9.4.9 for details).', 'Non-steroid eye drops', 'Vasoconstrictor eye drops are not allowed during the study.', 'Other non-steroid drops such as saline or methylcellulose are', 'allowed but should not be used on the day of a clinic visit.', 'Selenium or biotin for TED', '3 weeks prior to Screening through study completion. A', 'multivitamin containing selenium and/or biotin is allowed.', 'Rituximab (Rituxan\u00ae or MabThera\u00ae)', 'or', 'Any previous use or anticipated use during the study.', 'tocilizumab (Actemra\u00ae or Roactemra)', 'Non-steroid immunosuppressive agent (other than', '3 months prior to Screening through study completion.', 'rituximab or tocilizumab)', 'Investigational agent', '60 days prior to Screening through study completion.', 'Illicit drug/alcohol use', 'History of abuse within the past 2 years or abuse during', 'study.', 'Hearing loss and/or ototoxicity is not considered to be an adverse event causally associated with', 'the use of teprotumumab. However, it may be reasonable to avoid ototoxic medications such as', 'systemic administration of aminoglycoside and platinum-based chemotherapy during the study.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 77 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'The following medications may cause muscle spasm/cramps and should be avoided during the', 'study: donepezil, neostigmine, and vincristine.', 'All concomitant treatment (for TED and other conditions) in the Treatment Period and the', 'Follow-Up Period must be documented in the eCRF.', '9.4.10 Treatment Compliance', 'The Investigator is responsible for ensuring that dosing is administered in compliance with the', 'protocol. Delegation of this task must be clearly documented and approved by the Investigator.', 'All infusions of study medication will be administered at the clinic under the supervision of', 'clinic staff. Infusion volumes, and start and stop times of the infusions will be recorded in the', 'eCRF.', 'An inventory of the study medication supplies will be performed by the site or authorized study', \"designee and recorded onto the Drug Accountability Log in the subject's source document\", 'records or equivalent.', '9.5 Efficacy, Quality-of-Life, Pharmacokinetic, and Safety Variables', 'The Schedule of Assessments was previously provided in Section 2.1.', '9.5.1 Efficacy Variables', 'Efficacy assessments will be performed for both eyes at each assessment time point. The most', 'severely affected eye will be defined as the \"study eye\" at the Baseline (Day 1) Visit. If there is a', 'discrepancy between CAS and proptosis in determining the study eye, this will be adjudicated', 'always to the eye with the most significant proptosis. If both eyes are affected equally, the', 'Investigator will choose the \"study eye\". Both eyes will be assessed for efficacy but the study', 'eye will be used to assess the primary outcome measure.', 'Efficacy will be assessed by proptosis (measured as exophthalmos evaluation of the Clinical', 'Measures of Severity using a Hertel instrument provided by the Sponsor for consistency in', 'measurement), CAS (7-item scale), diplopia (measured as part of the Clinical Measures of', 'Severity) and Clinical Measures of Severity (including motility restriction assessments).', '9.5.1.1 Proptosis (Exophthalmos)', 'The most severely affected eye will be defined as the \"study eye\" at the Baseline (Day 1) Visit.', 'Proptosis assessments will be performed using a Hertel exophthalmometer provided by the', 'Sponsor for consistency in measurement, and (except when strictly unavoidable) the same Hertel', 'instrument and same observer should be used at each evaluation for the full duration of the study.', 'Additionally, the same intercanthal distance (ICD) must be used on each occasion. Instructions', 'for the measurement of proptosis are included in Section 17.2.', 'Proptosis will be measured for each eye at Screening, Day 1 and Weeks 6, 12, 18, and 24 (or', 'premature withdrawal [PW]) during the Treatment Period, and at Weeks 28, 36, 48, 60, and 72', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 78 of 117']\n\n###\n\n", "completion": "END"}